Sonnet Historical Financial Ratios

SONN Stock

USD 2.63 0.14 5.05%

Sonnet Biotherapeutics is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 34 K, Invested Capital of 0.0, Average Payables of 3.6 M or Stock Based Compensation To Revenue of 1.41 will help investors to properly organize and evaluate Sonnet Biotherapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Sonnet Financial Ratios Analysis

Sonnet BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sonnet Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sonnet financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sonnet Biotherapeutics history.

Sonnet Biotherapeutics Financial Ratios Chart

At this time, Sonnet Biotherapeutics' Graham Number is very stable compared to the past year. As of the 29th of November 2024, Shareholders Equity Per Share is likely to grow to about 33 K, while Price To Sales Ratio is likely to drop 1.12.

Price To Sales Ratio Days Sales Outstanding Average Payables Ev To Sales

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Sonnet Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sonnet Biotherapeutics sales, a figure that is much harder to manipulate than other Sonnet Biotherapeutics Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most ratios from Sonnet Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2024 (projected)
Interest Debt Per Share	0.003788	29.4K
Revenue Per Share	1.77	91.8K

Interest Debt Per Share Revenue Per Share

Sonnet Biotherapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.01	0.53	-0.34	-0.48	0.35	-0.14	0.35	0.01	0.99	0.54	0.26	-0.35	0.45	-0.87	-0.53	-0.33	0.41	-0.31	0.42	-0.56	0.76	0.4	0.56	0.78	0.26
Ptb Ratio	0.01		-0.33	0.34	0.8	-0.15	-0.09	-0.51	1.0	-0.06	-0.19	-0.89	-0.31	-0.35	-0.29	-0.03	0.18	-0.73	0.34	-0.21	-0.53	-0.17	-0.36	0.2	-0.48	-0.89
Days Sales Outstanding	0.53	-0.33		-0.73	-0.45	0.38	0.25	0.35	-0.33	0.54	0.54	0.28	-0.59	0.74	-0.46	-0.7	-0.4	0.36	-0.68	0.59	-0.27	0.64	0.63	0.36	0.75	0.28
Book Value Per Share	-0.34	0.34	-0.73		0.3	-0.44	-0.2	-0.24	0.34	-0.34	-0.5	-0.19	0.08	-0.99	0.32	0.17	0.39	-0.25	0.92	-0.33	0.18	-0.27	-0.42	-0.25	-0.36	-0.2
Free Cash Flow Yield	-0.48	0.8	-0.45	0.3		-0.31	0.06	-0.81	0.8	-0.56	-0.45	-0.91	-0.09	-0.38	0.22	0.31	0.21	-0.97	0.31	-0.43	-0.11	-0.56	-0.55	-0.31	-0.81	-0.91
Operating Cash Flow Per Share	0.35	-0.15	0.38	-0.44	-0.31		0.03	0.25	-0.15	0.36	0.97	0.19	0.09	0.47	-0.31	0.0	0.05	0.26	-0.71	0.09	-0.16	-0.06	0.38	0.24	0.27	0.19
Average Payables	-0.14	-0.09	0.25	-0.2	0.06	0.03		-0.07	-0.09	-0.15	0.03	-0.04	-0.16	0.16	0.12	-0.1	-0.16	-0.08	-0.19	0.1	0.07	-0.02	0.12	-0.09	0.0	-0.04
Capex To Depreciation	0.35	-0.51	0.35	-0.24	-0.81	0.25	-0.07		-0.51	0.44	0.36	0.55	-0.08	0.32	-0.37	-0.41	-0.15	0.92	-0.26	0.35	0.07	0.47	0.45	0.69	0.62	0.56
Pb Ratio	0.01	1.0	-0.33	0.34	0.8	-0.15	-0.09	-0.51		-0.06	-0.19	-0.89	-0.31	-0.35	-0.29	-0.03	0.18	-0.73	0.34	-0.21	-0.53	-0.17	-0.36	0.2	-0.48	-0.89
Ev To Sales	0.99	-0.06	0.54	-0.34	-0.56	0.36	-0.15	0.44	-0.06		0.56	0.33	-0.33	0.45	-0.86	-0.54	-0.33	0.5	-0.32	0.44	-0.51	0.78	0.43	0.59	0.82	0.33
Free Cash Flow Per Share	0.54	-0.19	0.54	-0.5	-0.45	0.97	0.03	0.36	-0.19	0.56		0.27	-0.06	0.54	-0.47	-0.2	-0.03	0.38	-0.72	0.26	-0.25	0.19	0.52	0.36	0.49	0.27
Roic	0.26	-0.89	0.28	-0.19	-0.91	0.19	-0.04	0.55	-0.89	0.33	0.27		0.34	0.25	0.13	-0.05	-0.17	0.83	-0.21	0.25	0.2	0.34	0.35	-0.06	0.61	1.0
Inventory Turnover	-0.35	-0.31	-0.59	0.08	-0.09	0.09	-0.16	-0.08	-0.31	-0.33	-0.06	0.34		-0.1	0.54	0.88	0.15	0.1	0.0	-0.45	0.31	-0.58	-0.32	-0.42	-0.43	0.33
Net Income Per Share	0.45	-0.35	0.74	-0.99	-0.38	0.47	0.16	0.32	-0.35	0.45	0.54	0.25	-0.1		-0.41	-0.23	-0.38	0.33	-0.9	0.39	-0.22	0.36	0.48	0.32	0.44	0.25
Days Of Inventory On Hand	-0.87	-0.29	-0.46	0.32	0.22	-0.31	0.12	-0.37	-0.29	-0.86	-0.47	0.13	0.54	-0.41		0.57	0.3	-0.24	0.29	-0.35	0.53	-0.65	-0.32	-0.77	-0.58	0.13
Payables Turnover	-0.53	-0.03	-0.7	0.17	0.31	0.0	-0.1	-0.41	-0.03	-0.54	-0.2	-0.05	0.88	-0.23	0.57		0.19	-0.3	0.1	-0.57	0.43	-0.77	-0.47	-0.6	-0.68	-0.06
Average Inventory	-0.33	0.18	-0.4	0.39	0.21	0.05	-0.16	-0.15	0.18	-0.33	-0.03	-0.17	0.15	-0.38	0.3	0.19		-0.23	0.33	0.08	0.15	-0.24	0.11	-0.23	-0.33	-0.17
Capex To Revenue	0.41	-0.73	0.36	-0.25	-0.97	0.26	-0.08	0.92	-0.73	0.5	0.38	0.83	0.1	0.33	-0.24	-0.3	-0.23		-0.27	0.33	0.12	0.5	0.45	0.46	0.72	0.83
Cash Per Share	-0.31	0.34	-0.68	0.92	0.31	-0.71	-0.19	-0.26	0.34	-0.32	-0.72	-0.21	0.0	-0.9	0.29	0.1	0.33	-0.27		-0.14	0.16	-0.08	-0.33	-0.24	-0.31	-0.21
Pocfratio	0.42	-0.21	0.59	-0.33	-0.43	0.09	0.1	0.35	-0.21	0.44	0.26	0.25	-0.45	0.39	-0.35	-0.57	0.08	0.33	-0.14		-0.16	0.77	0.94	0.28	0.65	0.25
Interest Coverage	-0.56	-0.53	-0.27	0.18	-0.11	-0.16	0.07	0.07	-0.53	-0.51	-0.25	0.2	0.31	-0.22	0.53	0.43	0.15	0.12	0.16	-0.16		-0.35	-0.04	-0.52	-0.16	0.21
Capex To Operating Cash Flow	0.76	-0.17	0.64	-0.27	-0.56	-0.06	-0.02	0.47	-0.17	0.78	0.19	0.34	-0.58	0.36	-0.65	-0.77	-0.24	0.5	-0.08	0.77	-0.35		0.64	0.5	0.87	0.35
Pfcf Ratio	0.4	-0.36	0.63	-0.42	-0.55	0.38	0.12	0.45	-0.36	0.43	0.52	0.35	-0.32	0.48	-0.32	-0.47	0.11	0.45	-0.33	0.94	-0.04	0.64		0.26	0.67	0.36
Days Payables Outstanding	0.56	0.2	0.36	-0.25	-0.31	0.24	-0.09	0.69	0.2	0.59	0.36	-0.06	-0.42	0.32	-0.77	-0.6	-0.23	0.46	-0.24	0.28	-0.52	0.5	0.26		0.44	-0.05
Income Quality	0.78	-0.48	0.75	-0.36	-0.81	0.27	0.0	0.62	-0.48	0.82	0.49	0.61	-0.43	0.44	-0.58	-0.68	-0.33	0.72	-0.31	0.65	-0.16	0.87	0.67	0.44		0.61
Roe	0.26	-0.89	0.28	-0.2	-0.91	0.19	-0.04	0.56	-0.89	0.33	0.27	1.0	0.33	0.25	0.13	-0.06	-0.17	0.83	-0.21	0.25	0.21	0.35	0.36	-0.05	0.61

Click cells to compare fundamentals

Sonnet Biotherapeutics Account Relationship Matchups

Sonnet Biotherapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	1.28	1.18	245.82	145.84	160.99	1.12
Ptb Ratio	4.88	64.07	5.34	(20.1)	(105.3)	5.12
Book Value Per Share	18.8K	98.74	279.3	(12.86)	(0.22)	34.0K
Free Cash Flow Yield	(0.0775)	(0.0811)	(0.19)	(0.56)	(0.92)	(0.0813)
Operating Cash Flow Per Share	(2.5K)	(510.54)	(282.97)	(140.22)	(20.56)	(2.7K)
Capex To Depreciation	0.94	1.31	0.0381	9.61	5.85	1.85
Pb Ratio	4.88	64.07	5.34	(20.1)	(105.3)	5.12
Free Cash Flow Per Share	(6.4K)	(513.03)	(283.01)	(144.76)	(20.98)	(6.7K)
Roic	(0.16)	(9.8)	(1.13)	11.71	83.16	(0.15)
Net Income Per Share	(15.6K)	(1.0K)	(313.76)	(150.79)	(18.14)	(16.4K)
Payables Turnover	12.57	0.0283	4.4	0.0196	5.37	6.53
Sales General And Administrative To Revenue	0.11	0.0118	18.48	24.5	48.21	0.0112
Capex To Revenue	0.0392	0.0553	0.007491	2.56	3.0	0.0525
Cash Per Share	1.2K	240.31	346.58	15.46	2.19	1.6K
Pocfratio	(32.67)	(12.39)	(5.27)	(1.84)	(1.11)	(34.31)
Capex To Operating Cash Flow	(1.53)	(0.004879)	(1.61E-4)	(0.0324)	(0.0208)	(1.45)
Pfcf Ratio	(12.91)	(12.33)	(5.27)	(1.79)	(1.09)	(13.56)
Days Payables Outstanding	29.03	12.9K	82.97	18.6K	68.03	27.58
Income Quality	0.16	0.64	0.9	0.93	1.13	0.15
Roe	(0.92)	(10.29)	(1.12)	11.73	83.34	(0.88)
Ev To Operating Cash Flow	(41.52)	(11.94)	(4.05)	(1.74)	(1.02)	(43.59)
Pe Ratio	(5.29)	(6.23)	(4.75)	(1.71)	(1.26)	(5.55)
Return On Tangible Assets	(1.63)	(3.89)	(0.86)	(5.11)	(3.47)	(1.72)
Ev To Free Cash Flow	(16.4)	(11.89)	(4.05)	(1.69)	(1.0)	(17.22)
Earnings Yield	(0.19)	(0.16)	(0.21)	(0.58)	(0.79)	(0.2)
Net Debt To E B I T D A	(2.65)	0.29	1.1	0.0946	0.11	(2.52)
Current Ratio	0.1	1.62	4.3	0.66	0.86	0.098
Tangible Book Value Per Share	(39.4K)	98.74	279.3	(12.86)	(0.22)	(37.5K)
Graham Number	77.0K	1.5K	1.4K	208.85	9.43	124.6K
Shareholders Equity Per Share	16.9K	98.74	279.3	(12.86)	(0.22)	33.0K

When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:

How To Invest In Sonnet

Details

Is Sonnet Stock a good investment?

Details

What is Sonnet Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.96)

Revenue Per Share

0.019

Quarterly Revenue Growth

(0.50)

Return On Assets

(0.97)

Return On Equity

(2.65)

The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Sonnet Historical Financial Ratios

About Sonnet Financial Ratios Analysis

Sonnet Biotherapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Ev To Sales

Sonnet Biotherapeutics fundamentals Correlations

Sonnet Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sonnet Biotherapeutics fundamentals Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Roe	+ 1.0	Roic
Ev To Sales	+ 0.99	Price To Sales Ratio
Free Cash Flow Per Share	+ 0.97	Operating Cash Flow Per Share
Pfcf Ratio	+ 0.94	Pocfratio
Cash Per Share	+ 0.92	Book Value Per Share

Net Income Per Share	- 0.99	Book Value Per Share
Capex To Revenue	- 0.97	Free Cash Flow Yield
Roe	- 0.91	Free Cash Flow Yield
Roic	- 0.91	Free Cash Flow Yield
Cash Per Share	- 0.9	Net Income Per Share
Roe	- 0.89	Pb Ratio